Summary

The global Microphysiological System and Organoids market is projected to grow from US$ 150 million in 2025 to US$ 438 million by 2032, at a CAGR of 16.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Microphysiological System and Organoids refers to a new generation of advanced in vitro biological models that combine microengineering, microfluidics, tissue engineering, stem cell technology, and three-dimensional cell culture technologies to replicate human physiological structures, organ functions, and disease characteristics. Microphysiological System (MPS) platforms integrate living human cells, biomaterials, and controlled microenvironments, while Organoids provide three-dimensional self-organized tissue models with organ-specific cellular functions. The research scope mainly covers human organ and tissue models, disease models, and non-human species models based on Organ-on-a-Chip, Tissue-on-a-Chip, Body-on-a-Chip, and related organoid technologies, with applications in pharmaceutical and biotechnology research, drug discovery, toxicology evaluation, disease modeling, and advanced biomedical studies.
Key Findings
Microphysiological System and Organoids are becoming important human-relevant models for pharmaceutical research and biomedical innovation
Organ-on-a-Chip and organoid-based platforms represent the core technology directions of the market
Human organ and tissue models are the primary application focus for improving preclinical prediction capabilities
Microfluidic-based MPS remains the leading technology architecture for commercial platform development
Pharmaceutical and biotechnology companies represent the major end-user group for Microphysiological System and Organoids applications
Market Trends
The Microphysiological System and Organoids industry is transitioning from traditional single-organ simulation toward more complex biological systems integrating multiple organs, patient-derived cells, advanced biomaterials, biosensing technologies, and artificial intelligence-based analysis. The combination of organ-on-chip platforms and organoid technologies is improving the ability to reproduce human physiological environments, disease mechanisms, and drug responses. Future development is expected to focus on higher biological complexity, improved reproducibility, automated testing workflows, and broader integration into pharmaceutical development processes.
Market Dynamics
Drivers
The major drivers of Microphysiological System and Organoids adoption include increasing demand for predictive human-based models in drug discovery, growing investment in pharmaceutical innovation, and rising interest in alternatives to traditional animal testing methods. These technologies provide opportunities to improve evaluation of drug efficacy, toxicity, pharmacokinetics, and disease mechanisms by better representing human biological responses compared with conventional in vitro models.
Restraints
Market development is constrained by technical complexity, limited standardization, difficulties in large-scale manufacturing, and challenges in achieving consistent biological performance across different laboratories. The integration of living cells, microfluidic systems, biomaterials, and analytical technologies increases development requirements and creates barriers for broader commercialization.
Opportunities
Future opportunities are emerging from personalized medicine, patient-derived organoid models, precision therapeutics, high-throughput drug screening, and integration with automated platforms and artificial intelligence. The combination of Microphysiological System and Organoids is expected to expand applications in complex disease modeling, drug response prediction, and translational biomedical research.
Challenges
The industry faces challenges related to regulatory acceptance, validation standards, reproducibility, and integration into established pharmaceutical development workflows. Although Microphysiological System and Organoids provide improved human relevance, broader adoption requires further demonstration of reliability, scalability, and compatibility with regulatory requirements.
Industry Chain Analysis
The Microphysiological System and Organoids industry chain includes upstream suppliers of stem cells, primary cells, biomaterials, microfluidic chips, sensors, culture materials, and laboratory equipment. Midstream companies develop platforms by integrating cell biology, tissue engineering, microfabrication, and analytical technologies to create organ models, disease models, and multi-organ systems. Downstream users mainly include pharmaceutical and biotechnology companies, academic and research institutes, and other biomedical organizations. The core value creation process focuses on improving biological prediction accuracy, accelerating drug development, and providing more human-relevant experimental models.
Segment Insights
By type, Microphysiological System and Organoids can be categorized into Human Organ and Tissue Models, Disease Models, and Non-Human Species Models. Human organ and tissue models represent the most commercially relevant direction due to their applications in drug evaluation and physiological simulation. By technology platform, Organ-on-a-Chip, Tissue-on-a-Chip, and Body-on-a-Chip represent major development pathways, while organoid-integrated systems provide opportunities for more complex biological modeling. By technology architecture, Microfluidic-based MPS remains the dominant platform, while 3D Bioprinting-based MPS, Scaffold-based Tissue Engineering MPS, and Sensor-integrated MPS continue to expand technological possibilities.
Downstream Market Opportunities
The primary downstream opportunity for Microphysiological System and Organoids is pharmaceutical and biotechnology research, where these technologies are applied in drug discovery, toxicity testing, efficacy evaluation, and preclinical validation. Academic and research institutes remain important users for disease mechanism studies and technology development. Emerging applications include personalized medicine, patient-specific therapeutic evaluation, oncology research, and advanced biological modeling.
Regional Insights
North America represents one of the leading regions for Microphysiological System and Organoids development due to strong pharmaceutical research capabilities, biotechnology innovation, and early adoption of advanced biomedical technologies. Europe has established significant capabilities through life science research networks and alternative testing technology development. Asia-Pacific is becoming an increasingly important market supported by pharmaceutical expansion, biotechnology investment, and growing research capabilities in China, Japan, and other countries.
Competitive Landscape Analysis
The Microphysiological System and Organoids market is characterized by specialized biotechnology companies, research organizations, and platform developers focusing on different organ models, disease applications, and technology architectures. Competition mainly centers on biological relevance, platform scalability, model validation, integration capability, and compatibility with pharmaceutical workflows. Companies developing organ-on-chip platforms, organoid-based systems, multi-organ models, and automated testing solutions are strengthening their positions as the industry moves from academic research toward broader commercial applications.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Microphysiological System and Organoids market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Emulate
Mimetas
TissUse
InSphero
CN Bio
Hesperos
28bio
Beijing Daxiang Biotech
Nortis (Quris-Al)
NETRI
Bi/ond
AlveoliX
BiomimX
React4Life
SynVivo
Ananda Devices
Dynamic42
BEOnChip
Altis Biosystems
Newcells Biotech
ImmuONE
TNO
Valo Health (TARA Biosystems)
Draper Laboratory
Cherry Biotech
Obatala Sciences
Aracari Bio
StemPharm
AVATARGET
Suzhou Jiyan Biopharmaceutical
Segment by Type
Human Organ and Tissue Models
Disease Models
Non-Human Species Models
Segment by Technology Platform
Organ-on-a-Chip
Tissue-on-a-Chip
Body-on-a-Chip
Others
Segment by Technology Architecture
Microfluidic-based MPS
3D Bioprinting-based MPS
Scaffold-based Tissue Engineering MPS
Sensor-integrated MPS
Segment by Application
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Microphysiological System and Organoids study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Microphysiological System and Organoids: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Microphysiological System and Organoids Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Human Organ and Tissue Models
1.2.3 Disease Models
1.2.4 Non-Human Species Models
1.3 Market Segmentation by Technology Platform
1.3.1 Global Microphysiological System and Organoids Market Size by Technology Platform, 2021 vs 2025 vs 2032
1.3.2 Organ-on-a-Chip
1.3.3 Tissue-on-a-Chip
1.3.4 Body-on-a-Chip
1.3.5 Others
1.4 Market Segmentation by Technology Architecture
1.4.1 Global Microphysiological System and Organoids Market Size by Technology Architecture, 2021 vs 2025 vs 2032
1.4.2 Microfluidic-based MPS
1.4.3 3D Bioprinting-based MPS
1.4.4 Scaffold-based Tissue Engineering MPS
1.4.5 Sensor-integrated MPS
1.5 Market Segmentation by Application
1.5.1 Global Microphysiological System and Organoids Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical & Biotechnology Companies
1.5.3 Academic & Research Institutes
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Microphysiological System and Organoids Revenue Estimates and Forecasts (2021-2032)
2.2 Global Microphysiological System and Organoids Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Microphysiological System and Organoids Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Microphysiological System and Organoids Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Human Organ and Tissue Models: Market Share by Key Players
3.3.2 Disease Models: Market Share by Key Players
3.3.3 Non-Human Species Models: Market Share by Key Players
3.4 Global Microphysiological System and Organoids Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Microphysiological System and Organoids Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Microphysiological System and Organoids Market by Technology Platform
4.2.1 Global Revenue by Technology Platform (2021-2032)
4.2.2 Global Revenue-Based Market Share by Technology Platform (2021-2032)
4.3 Global Microphysiological System and Organoids Market by Technology Architecture
4.3.1 Global Revenue by Technology Architecture (2021-2032)
4.3.2 Global Revenue-Based Market Share by Technology Architecture (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Microphysiological System and Organoids Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Microphysiological System and Organoids Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Microphysiological System and Organoids Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Microphysiological System and Organoids Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Microphysiological System and Organoids Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Microphysiological System and Organoids Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Microphysiological System and Organoids Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Microphysiological System and Organoids Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Microphysiological System and Organoids Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Microphysiological System and Organoids Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Microphysiological System and Organoids Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Emulate
11.1.1 Emulate Corporation Information
11.1.2 Emulate Business Overview
11.1.3 Emulate Microphysiological System and Organoids Product Features and Attributes
11.1.4 Emulate Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.1.5 Emulate Microphysiological System and Organoids Revenue by Product in 2025
11.1.6 Emulate Microphysiological System and Organoids Revenue by Application in 2025
11.1.7 Emulate Microphysiological System and Organoids Revenue by Geographic Area in 2025
11.1.8 Emulate Microphysiological System and Organoids SWOT Analysis
11.1.9 Emulate Recent Developments
11.2 Mimetas
11.2.1 Mimetas Corporation Information
11.2.2 Mimetas Business Overview
11.2.3 Mimetas Microphysiological System and Organoids Product Features and Attributes
11.2.4 Mimetas Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.2.5 Mimetas Microphysiological System and Organoids Revenue by Product in 2025
11.2.6 Mimetas Microphysiological System and Organoids Revenue by Application in 2025
11.2.7 Mimetas Microphysiological System and Organoids Revenue by Geographic Area in 2025
11.2.8 Mimetas Microphysiological System and Organoids SWOT Analysis
11.2.9 Mimetas Recent Developments
11.3 TissUse
11.3.1 TissUse Corporation Information
11.3.2 TissUse Business Overview
11.3.3 TissUse Microphysiological System and Organoids Product Features and Attributes
11.3.4 TissUse Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.3.5 TissUse Microphysiological System and Organoids Revenue by Product in 2025
11.3.6 TissUse Microphysiological System and Organoids Revenue by Application in 2025
11.3.7 TissUse Microphysiological System and Organoids Revenue by Geographic Area in 2025
11.3.8 TissUse Microphysiological System and Organoids SWOT Analysis
11.3.9 TissUse Recent Developments
11.4 InSphero
11.4.1 InSphero Corporation Information
11.4.2 InSphero Business Overview
11.4.3 InSphero Microphysiological System and Organoids Product Features and Attributes
11.4.4 InSphero Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.4.5 InSphero Microphysiological System and Organoids Revenue by Product in 2025
11.4.6 InSphero Microphysiological System and Organoids Revenue by Application in 2025
11.4.7 InSphero Microphysiological System and Organoids Revenue by Geographic Area in 2025
11.4.8 InSphero Microphysiological System and Organoids SWOT Analysis
11.4.9 InSphero Recent Developments
11.5 CN Bio
11.5.1 CN Bio Corporation Information
11.5.2 CN Bio Business Overview
11.5.3 CN Bio Microphysiological System and Organoids Product Features and Attributes
11.5.4 CN Bio Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.5.5 CN Bio Microphysiological System and Organoids Revenue by Product in 2025
11.5.6 CN Bio Microphysiological System and Organoids Revenue by Application in 2025
11.5.7 CN Bio Microphysiological System and Organoids Revenue by Geographic Area in 2025
11.5.8 CN Bio Microphysiological System and Organoids SWOT Analysis
11.5.9 CN Bio Recent Developments
11.6 Hesperos
11.6.1 Hesperos Corporation Information
11.6.2 Hesperos Business Overview
11.6.3 Hesperos Microphysiological System and Organoids Product Features and Attributes
11.6.4 Hesperos Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.6.5 Hesperos Recent Developments
11.7 28bio
11.7.1 28bio Corporation Information
11.7.2 28bio Business Overview
11.7.3 28bio Microphysiological System and Organoids Product Features and Attributes
11.7.4 28bio Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.7.5 28bio Recent Developments
11.8 Beijing Daxiang Biotech
11.8.1 Beijing Daxiang Biotech Corporation Information
11.8.2 Beijing Daxiang Biotech Business Overview
11.8.3 Beijing Daxiang Biotech Microphysiological System and Organoids Product Features and Attributes
11.8.4 Beijing Daxiang Biotech Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.8.5 Beijing Daxiang Biotech Recent Developments
11.9 Nortis (Quris-Al)
11.9.1 Nortis (Quris-Al) Corporation Information
11.9.2 Nortis (Quris-Al) Business Overview
11.9.3 Nortis (Quris-Al) Microphysiological System and Organoids Product Features and Attributes
11.9.4 Nortis (Quris-Al) Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.9.5 Nortis (Quris-Al) Recent Developments
11.10 NETRI
11.10.1 NETRI Corporation Information
11.10.2 NETRI Business Overview
11.10.3 NETRI Microphysiological System and Organoids Product Features and Attributes
11.10.4 NETRI Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Bi/ond
11.11.1 Bi/ond Corporation Information
11.11.2 Bi/ond Business Overview
11.11.3 Bi/ond Microphysiological System and Organoids Product Features and Attributes
11.11.4 Bi/ond Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.11.5 Bi/ond Recent Developments
11.12 AlveoliX
11.12.1 AlveoliX Corporation Information
11.12.2 AlveoliX Business Overview
11.12.3 AlveoliX Microphysiological System and Organoids Product Features and Attributes
11.12.4 AlveoliX Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.12.5 AlveoliX Recent Developments
11.13 BiomimX
11.13.1 BiomimX Corporation Information
11.13.2 BiomimX Business Overview
11.13.3 BiomimX Microphysiological System and Organoids Product Features and Attributes
11.13.4 BiomimX Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.13.5 BiomimX Recent Developments
11.14 React4Life
11.14.1 React4Life Corporation Information
11.14.2 React4Life Business Overview
11.14.3 React4Life Microphysiological System and Organoids Product Features and Attributes
11.14.4 React4Life Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.14.5 React4Life Recent Developments
11.15 SynVivo
11.15.1 SynVivo Corporation Information
11.15.2 SynVivo Business Overview
11.15.3 SynVivo Microphysiological System and Organoids Product Features and Attributes
11.15.4 SynVivo Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.15.5 SynVivo Recent Developments
11.16 Ananda Devices
11.16.1 Ananda Devices Corporation Information
11.16.2 Ananda Devices Business Overview
11.16.3 Ananda Devices Microphysiological System and Organoids Product Features and Attributes
11.16.4 Ananda Devices Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.16.5 Ananda Devices Recent Developments
11.17 Dynamic42
11.17.1 Dynamic42 Corporation Information
11.17.2 Dynamic42 Business Overview
11.17.3 Dynamic42 Microphysiological System and Organoids Product Features and Attributes
11.17.4 Dynamic42 Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.17.5 Dynamic42 Recent Developments
11.18 BEOnChip
11.18.1 BEOnChip Corporation Information
11.18.2 BEOnChip Business Overview
11.18.3 BEOnChip Microphysiological System and Organoids Product Features and Attributes
11.18.4 BEOnChip Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.18.5 BEOnChip Recent Developments
11.19 Altis Biosystems
11.19.1 Altis Biosystems Corporation Information
11.19.2 Altis Biosystems Business Overview
11.19.3 Altis Biosystems Microphysiological System and Organoids Product Features and Attributes
11.19.4 Altis Biosystems Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.19.5 Altis Biosystems Recent Developments
11.20 Newcells Biotech
11.20.1 Newcells Biotech Corporation Information
11.20.2 Newcells Biotech Business Overview
11.20.3 Newcells Biotech Microphysiological System and Organoids Product Features and Attributes
11.20.4 Newcells Biotech Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.20.5 Newcells Biotech Recent Developments
11.21 ImmuONE
11.21.1 ImmuONE Corporation Information
11.21.2 ImmuONE Business Overview
11.21.3 ImmuONE Microphysiological System and Organoids Product Features and Attributes
11.21.4 ImmuONE Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.21.5 ImmuONE Recent Developments
11.22 TNO
11.22.1 TNO Corporation Information
11.22.2 TNO Business Overview
11.22.3 TNO Microphysiological System and Organoids Product Features and Attributes
11.22.4 TNO Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.22.5 TNO Recent Developments
11.23 Valo Health (TARA Biosystems)
11.23.1 Valo Health (TARA Biosystems) Corporation Information
11.23.2 Valo Health (TARA Biosystems) Business Overview
11.23.3 Valo Health (TARA Biosystems) Microphysiological System and Organoids Product Features and Attributes
11.23.4 Valo Health (TARA Biosystems) Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.23.5 Valo Health (TARA Biosystems) Recent Developments
11.24 Draper Laboratory
11.24.1 Draper Laboratory Corporation Information
11.24.2 Draper Laboratory Business Overview
11.24.3 Draper Laboratory Microphysiological System and Organoids Product Features and Attributes
11.24.4 Draper Laboratory Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.24.5 Draper Laboratory Recent Developments
11.25 Cherry Biotech
11.25.1 Cherry Biotech Corporation Information
11.25.2 Cherry Biotech Business Overview
11.25.3 Cherry Biotech Microphysiological System and Organoids Product Features and Attributes
11.25.4 Cherry Biotech Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.25.5 Cherry Biotech Recent Developments
11.26 Obatala Sciences
11.26.1 Obatala Sciences Corporation Information
11.26.2 Obatala Sciences Business Overview
11.26.3 Obatala Sciences Microphysiological System and Organoids Product Features and Attributes
11.26.4 Obatala Sciences Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.26.5 Obatala Sciences Recent Developments
11.27 Aracari Bio
11.27.1 Aracari Bio Corporation Information
11.27.2 Aracari Bio Business Overview
11.27.3 Aracari Bio Microphysiological System and Organoids Product Features and Attributes
11.27.4 Aracari Bio Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.27.5 Aracari Bio Recent Developments
11.28 StemPharm
11.28.1 StemPharm Corporation Information
11.28.2 StemPharm Business Overview
11.28.3 StemPharm Microphysiological System and Organoids Product Features and Attributes
11.28.4 StemPharm Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.28.5 StemPharm Recent Developments
11.29 AVATARGET
11.29.1 AVATARGET Corporation Information
11.29.2 AVATARGET Business Overview
11.29.3 AVATARGET Microphysiological System and Organoids Product Features and Attributes
11.29.4 AVATARGET Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.29.5 AVATARGET Recent Developments
11.30 Suzhou Jiyan Biopharmaceutical
11.30.1 Suzhou Jiyan Biopharmaceutical Corporation Information
11.30.2 Suzhou Jiyan Biopharmaceutical Business Overview
11.30.3 Suzhou Jiyan Biopharmaceutical Microphysiological System and Organoids Product Features and Attributes
11.30.4 Suzhou Jiyan Biopharmaceutical Microphysiological System and Organoids Revenue and Gross Margin (2021-2026)
11.30.5 Suzhou Jiyan Biopharmaceutical Recent Developments

12 Microphysiological System and Organoids Value Chain and Ecosystem Analysis
12.1 Microphysiological System and Organoids Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Microphysiological System and Organoids Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Microphysiological System and Organoids Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Microphysiological System and Organoids Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Microphysiological System and Organoids Market Size Growth Rate by Technology Platform, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Microphysiological System and Organoids Market Size Growth Rate by Technology Architecture, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Microphysiological System and Organoids Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Microphysiological System and Organoids Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Microphysiological System and Organoids Revenue by Region (US$ Million), 2021-2026
Table 7. Global Microphysiological System and Organoids Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Microphysiological System and Organoids Revenue by Players (US$ Million), 2021-2026
Table 10. Global Microphysiological System and Organoids Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Microphysiological System and Organoids Revenue, 2025
Table 13. Global Microphysiological System and Organoids Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Microphysiological System and Organoids Companies Headquarters
Table 15. Global Microphysiological System and Organoids Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Microphysiological System and Organoids Revenue by Type (US$ Million), 2021-2026
Table 19. Global Microphysiological System and Organoids Revenue by Type (US$ Million), 2027-2032
Table 20. Global Microphysiological System and Organoids Revenue by Technology Platform (US$ Million), 2021-2026
Table 21. Global Microphysiological System and Organoids Revenue by Technology Platform (US$ Million), 2027-2032
Table 22. Global Microphysiological System and Organoids Revenue by Technology Architecture (US$ Million), 2021-2026
Table 23. Global Microphysiological System and Organoids Revenue by Technology Architecture (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Microphysiological System and Organoids Revenue by Application (US$ Million), 2021-2026
Table 26. Global Microphysiological System and Organoids Revenue by Application (US$ Million), 2027-2032
Table 27. Microphysiological System and Organoids High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Microphysiological System and Organoids Growth Accelerators and Market Barriers
Table 31. North America Microphysiological System and Organoids Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Microphysiological System and Organoids Growth Accelerators and Market Barriers
Table 33. Europe Microphysiological System and Organoids Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Microphysiological System and Organoids Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Microphysiological System and Organoids Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Microphysiological System and Organoids Investment Opportunities and Key Challenges
Table 37. Central and South America Microphysiological System and Organoids Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Microphysiological System and Organoids Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Microphysiological System and Organoids Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Emulate Corporation Information
Table 41. Emulate Description and Major Businesses
Table 42. Emulate Product Features and Attributes
Table 43. Emulate Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Emulate Revenue Proportion by Product in 2025
Table 45. Emulate Revenue Proportion by Application in 2025
Table 46. Emulate Revenue Proportion by Geographic Area in 2025
Table 47. Emulate Microphysiological System and Organoids SWOT Analysis
Table 48. Emulate Recent Developments
Table 49. Mimetas Corporation Information
Table 50. Mimetas Description and Major Businesses
Table 51. Mimetas Product Features and Attributes
Table 52. Mimetas Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Mimetas Revenue Proportion by Product in 2025
Table 54. Mimetas Revenue Proportion by Application in 2025
Table 55. Mimetas Revenue Proportion by Geographic Area in 2025
Table 56. Mimetas Microphysiological System and Organoids SWOT Analysis
Table 57. Mimetas Recent Developments
Table 58. TissUse Corporation Information
Table 59. TissUse Description and Major Businesses
Table 60. TissUse Product Features and Attributes
Table 61. TissUse Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. TissUse Revenue Proportion by Product in 2025
Table 63. TissUse Revenue Proportion by Application in 2025
Table 64. TissUse Revenue Proportion by Geographic Area in 2025
Table 65. TissUse Microphysiological System and Organoids SWOT Analysis
Table 66. TissUse Recent Developments
Table 67. InSphero Corporation Information
Table 68. InSphero Description and Major Businesses
Table 69. InSphero Product Features and Attributes
Table 70. InSphero Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. InSphero Revenue Proportion by Product in 2025
Table 72. InSphero Revenue Proportion by Application in 2025
Table 73. InSphero Revenue Proportion by Geographic Area in 2025
Table 74. InSphero Microphysiological System and Organoids SWOT Analysis
Table 75. InSphero Recent Developments
Table 76. CN Bio Corporation Information
Table 77. CN Bio Description and Major Businesses
Table 78. CN Bio Product Features and Attributes
Table 79. CN Bio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. CN Bio Revenue Proportion by Product in 2025
Table 81. CN Bio Revenue Proportion by Application in 2025
Table 82. CN Bio Revenue Proportion by Geographic Area in 2025
Table 83. CN Bio Microphysiological System and Organoids SWOT Analysis
Table 84. CN Bio Recent Developments
Table 85. Hesperos Corporation Information
Table 86. Hesperos Description and Major Businesses
Table 87. Hesperos Product Features and Attributes
Table 88. Hesperos Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Hesperos Recent Developments
Table 90. 28bio Corporation Information
Table 91. 28bio Description and Major Businesses
Table 92. 28bio Product Features and Attributes
Table 93. 28bio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. 28bio Recent Developments
Table 95. Beijing Daxiang Biotech Corporation Information
Table 96. Beijing Daxiang Biotech Description and Major Businesses
Table 97. Beijing Daxiang Biotech Product Features and Attributes
Table 98. Beijing Daxiang Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Beijing Daxiang Biotech Recent Developments
Table 100. Nortis (Quris-Al) Corporation Information
Table 101. Nortis (Quris-Al) Description and Major Businesses
Table 102. Nortis (Quris-Al) Product Features and Attributes
Table 103. Nortis (Quris-Al) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Nortis (Quris-Al) Recent Developments
Table 105. NETRI Corporation Information
Table 106. NETRI Description and Major Businesses
Table 107. NETRI Product Features and Attributes
Table 108. NETRI Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. NETRI Recent Developments
Table 110. Bi/ond Corporation Information
Table 111. Bi/ond Description and Major Businesses
Table 112. Bi/ond Product Features and Attributes
Table 113. Bi/ond Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Bi/ond Recent Developments
Table 115. AlveoliX Corporation Information
Table 116. AlveoliX Description and Major Businesses
Table 117. AlveoliX Product Features and Attributes
Table 118. AlveoliX Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. AlveoliX Recent Developments
Table 120. BiomimX Corporation Information
Table 121. BiomimX Description and Major Businesses
Table 122. BiomimX Product Features and Attributes
Table 123. BiomimX Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. BiomimX Recent Developments
Table 125. React4Life Corporation Information
Table 126. React4Life Description and Major Businesses
Table 127. React4Life Product Features and Attributes
Table 128. React4Life Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. React4Life Recent Developments
Table 130. SynVivo Corporation Information
Table 131. SynVivo Description and Major Businesses
Table 132. SynVivo Product Features and Attributes
Table 133. SynVivo Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. SynVivo Recent Developments
Table 135. Ananda Devices Corporation Information
Table 136. Ananda Devices Description and Major Businesses
Table 137. Ananda Devices Product Features and Attributes
Table 138. Ananda Devices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Ananda Devices Recent Developments
Table 140. Dynamic42 Corporation Information
Table 141. Dynamic42 Description and Major Businesses
Table 142. Dynamic42 Product Features and Attributes
Table 143. Dynamic42 Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Dynamic42 Recent Developments
Table 145. BEOnChip Corporation Information
Table 146. BEOnChip Description and Major Businesses
Table 147. BEOnChip Product Features and Attributes
Table 148. BEOnChip Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. BEOnChip Recent Developments
Table 150. Altis Biosystems Corporation Information
Table 151. Altis Biosystems Description and Major Businesses
Table 152. Altis Biosystems Product Features and Attributes
Table 153. Altis Biosystems Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Altis Biosystems Recent Developments
Table 155. Newcells Biotech Corporation Information
Table 156. Newcells Biotech Description and Major Businesses
Table 157. Newcells Biotech Product Features and Attributes
Table 158. Newcells Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Newcells Biotech Recent Developments
Table 160. ImmuONE Corporation Information
Table 161. ImmuONE Description and Major Businesses
Table 162. ImmuONE Product Features and Attributes
Table 163. ImmuONE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. ImmuONE Recent Developments
Table 165. TNO Corporation Information
Table 166. TNO Description and Major Businesses
Table 167. TNO Product Features and Attributes
Table 168. TNO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. TNO Recent Developments
Table 170. Valo Health (TARA Biosystems) Corporation Information
Table 171. Valo Health (TARA Biosystems) Description and Major Businesses
Table 172. Valo Health (TARA Biosystems) Product Features and Attributes
Table 173. Valo Health (TARA Biosystems) Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Valo Health (TARA Biosystems) Recent Developments
Table 175. Draper Laboratory Corporation Information
Table 176. Draper Laboratory Description and Major Businesses
Table 177. Draper Laboratory Product Features and Attributes
Table 178. Draper Laboratory Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Draper Laboratory Recent Developments
Table 180. Cherry Biotech Corporation Information
Table 181. Cherry Biotech Description and Major Businesses
Table 182. Cherry Biotech Product Features and Attributes
Table 183. Cherry Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Cherry Biotech Recent Developments
Table 185. Obatala Sciences Corporation Information
Table 186. Obatala Sciences Description and Major Businesses
Table 187. Obatala Sciences Product Features and Attributes
Table 188. Obatala Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Obatala Sciences Recent Developments
Table 190. Aracari Bio Corporation Information
Table 191. Aracari Bio Description and Major Businesses
Table 192. Aracari Bio Product Features and Attributes
Table 193. Aracari Bio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Aracari Bio Recent Developments
Table 195. StemPharm Corporation Information
Table 196. StemPharm Description and Major Businesses
Table 197. StemPharm Product Features and Attributes
Table 198. StemPharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. StemPharm Recent Developments
Table 200. AVATARGET Corporation Information
Table 201. AVATARGET Description and Major Businesses
Table 202. AVATARGET Product Features and Attributes
Table 203. AVATARGET Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. AVATARGET Recent Developments
Table 205. Suzhou Jiyan Biopharmaceutical Corporation Information
Table 206. Suzhou Jiyan Biopharmaceutical Description and Major Businesses
Table 207. Suzhou Jiyan Biopharmaceutical Product Features and Attributes
Table 208. Suzhou Jiyan Biopharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. Suzhou Jiyan Biopharmaceutical Recent Developments
Table 210. Technologies, Platforms and Infrastructure
Table 211. Distributors List
Table 212. Market Trends and Market Evolution
Table 213. Market Drivers and Opportunities
Table 214. Market Challenges, Risks, and Restraints
Table 215. Research Programs/Design for This Report
Table 216. Key Data Information from Secondary Sources
Table 217. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Microphysiological System and Organoids Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Human Organ and Tissue Models Product Picture
Figure 3. Disease Models Product Picture
Figure 4. Non-Human Species Models Product Picture
Figure 5. Global Microphysiological System and Organoids Market Size Growth Rate by Technology Platform, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Organ-on-a-Chip Product Picture
Figure 7. Tissue-on-a-Chip Product Picture
Figure 8. Body-on-a-Chip Product Picture
Figure 9. Others Product Picture
Figure 10. Global Microphysiological System and Organoids Market Size Growth Rate by Technology Architecture, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Microfluidic-based MPS Product Picture
Figure 12. 3D Bioprinting-based MPS Product Picture
Figure 13. Scaffold-based Tissue Engineering MPS Product Picture
Figure 14. Sensor-integrated MPS Product Picture
Figure 15. Global Microphysiological System and Organoids Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Pharmaceutical & Biotechnology Companies
Figure 17. Academic & Research Institutes
Figure 18. Others
Figure 19. Microphysiological System and Organoids Report Years Considered
Figure 20. Global Microphysiological System and Organoids Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 22. Global Microphysiological System and Organoids Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Microphysiological System and Organoids Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Microphysiological System and Organoids Revenue-Based Market Share Ranking (2025)
Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 26. Human Organ and Tissue Models Revenue-Based Market Share by Player in 2025
Figure 27. Disease Models Revenue-Based Market Share by Player in 2025
Figure 28. Non-Human Species Models Revenue-Based Market Share by Player in 2025
Figure 29. Global Microphysiological System and Organoids Revenue-Based Market Share by Type (2021-2032)
Figure 30. Global Microphysiological System and Organoids Revenue-Based Market Share by Technology Platform (2021-2032)
Figure 31. Global Microphysiological System and Organoids Revenue-Based Market Share by Technology Architecture (2021-2032)
Figure 32. Global Microphysiological System and Organoids Revenue-Based Market Share by Application (2021-2032)
Figure 33. North America Microphysiological System and Organoids Revenue YoY (US$ Million), 2021-2032
Figure 34. North America Top 5 Players Microphysiological System and Organoids Revenue (US$ Million) in 2025
Figure 35. North America Microphysiological System and Organoids Revenue (US$ Million) by Application (2021-2032)
Figure 36. US Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 37. Canada Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 38. Mexico Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 39. Europe Microphysiological System and Organoids Revenue YoY (US$ Million), 2021-2032
Figure 40. Europe Top 5 Players Microphysiological System and Organoids Revenue (US$ Million) in 2025
Figure 41. Europe Microphysiological System and Organoids Revenue (US$ Million) by Application (2021-2032)
Figure 42. Germany Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 43. France Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 44. U.K. Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 45. Italy Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 46. Russia Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 47. Asia-Pacific Microphysiological System and Organoids Revenue YoY (US$ Million), 2021-2032
Figure 48. Asia-Pacific Top 8 Players Microphysiological System and Organoids Revenue (US$ Million) in 2025
Figure 49. Asia-Pacific Microphysiological System and Organoids Revenue (US$ Million) by Application (2021-2032)
Figure 50. Indonesia Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 51. Japan Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 52. South Korea Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 53. Australia Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 54. India Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 55. Indonesia Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 56. Vietnam Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 57. Malaysia Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 58. Philippines Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 59. Singapore Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 60. Central and South America Microphysiological System and Organoids Revenue YoY (US$ Million), 2021-2032
Figure 61. Central and South America Top 5 Players Microphysiological System and Organoids Revenue (US$ Million) in 2025
Figure 62. Central and South America Microphysiological System and Organoids Revenue (US$ Million) by Application (2021-2032)
Figure 63. Brazil Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 64. Argentina Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 65. Middle East and Africa Microphysiological System and Organoids Revenue YoY (US$ Million), 2021-2032
Figure 66. Middle East and Africa Top 5 Players Microphysiological System and Organoids Revenue (US$ Million) in 2025
Figure 67. Middle East and Africa Microphysiological System and Organoids Revenue (US$ Million) by Application (2021-2032)
Figure 68. GCC Countries Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 69. Israel Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 70. Egypt Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 71. South Africa Microphysiological System and Organoids Revenue (US$ Million), 2021-2032
Figure 72. Microphysiological System and Organoids Value Chain Mapping
Figure 73. Channels of Distribution (Direct Vs Distribution)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed